| Bioactivity | SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC50 of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models[1]. |
| Sequence | His-{L-Iva}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-{L-Iva}-Gln-Ala-Ala-Lys(AEEA-AEEA-gammaGlu-C18 diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly |
| Shortening | H-{L-Iva}-EGTFTSDVSSYLE-{L-Iva}-QAAK(AEEA-AEEA-gammaGlu-C18 diacid)-EFIAWLVRGRG |
| Formula | C191H299N45O59 |
| Molar Mass | 4169.68 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhao C, et al., Glp-1 agonist polypeptide compound and salt thereof, synthesis method therefor and use thereof. EP4108682. |